期刊
CARDIOLOGY
卷 115, 期 2, 页码 155-162出版社
KARGER
DOI: 10.1159/000265166
关键词
Adriamycin; Anthracyclines; Cardiomyocytes; Cardiomyopathy; Doxorubicin; Vincristine
资金
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068738] Funding Source: NIH RePORTER
- NHLBI NIH HHS [P01 HL068738, P01 HL068738-05] Funding Source: Medline
Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered. Copyright (C) 2009 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据